๐—Ÿ๐—ผ๐—ป๐—ด ๐—ง๐—ฒ๐—ฟ๐—บ ยฎโ„ข
19.7K subscribers
287 photos
3 files
17 links
In this Long term call monthly 1-3 call given holding period 1-3yrs
More premium Multibagger jackpot call msg me @Shortterm_bot

I am not SEBI registered analyst All the stocks are educational purpose,consulting your financial advisor before buying
Download Telegram
Best Small cap Mutual Fund
โšก11๐Ÿ”ฅ7๐Ÿ‘5๐Ÿ‘Œ3๐Ÿ˜1
๐Ÿ’ŠBest in PHARMA SECTOR

a) Lincoln Pharmaceuticals

b) Cipla

c) Piramal Pharma Ltd

d) Glenmark
๐Ÿ‘35โšก5๐Ÿ‘Œ3โค2๐Ÿ‘€1
Good morning
๐Ÿ†’5๐Ÿ‘1๐Ÿ”ฅ1๐Ÿ™1๐Ÿพ1
Lincoln Pharmaceuticals Limited report

Lincoln pharma India's leading healthcare Set up in the year 1979, the manufacturing facility of Lincoln is based at Khatraj, Gujarat sharing the same dais as with the international standards. There arecompanies has reported standalone net profit of Rs. 50.03 crore for the half year ended 30th September 2024, growth of 7.55% Y-O-Y as compared to the net profit of Rs. 46.52 crore in H1 FY24. Income from operation for the H1 FY25 was reported at Rs. 308.50 crore, higher by 5.79% Y-O-Y over H1 FY24 income from operation of Rs. 291.61 crore. EBITDA for the H1 FY25 ended September 2024 was reported at Rs. 71.50 crore as compared to Rs. 68.25 crore EBITDA in H1 FY24 registering growth of 4.76% Y-O-Y. EPS for H1 FY25 was reported at Rs. 24.96 per share. Shareholders at the 30th Annual General Meeting (AGM) approved a dividend of Rs. 1.80 per share (18%) for the FY 2023-24. As of September 2024, Foreign Institutional Investors (FIIs) have steadily raised their holding in the company to 5.19% from 2.59% as on September 2023. The company aims to reach a revenue target of Rs. 750 crore by FY26 through focused growth strategies, business expansion into high-value product lines, and entry into new markets. Company is also among a very few companies to achieve a profit growth every single year from FY13 to FY24. Commenting on the results and performance,
๐Ÿ‘4โค3โšก3๐Ÿ”ฅ1
Management comments

Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "We are pleased to report continued strong growth across all business verticals H1 FY25, while maintaining a net debt-free status. Our new product launches in domestic and export markets have strengthened our market presence and accelerated growth, positioning us for even better performance during the second half of the year. Through a combination of robust growth initiatives, high-quality products, geographic expansion, and operational improvements, we are on track to achieve our ambitious Rs. 750 crore revenue target by FY26. Notably, we are among a select group of companies that have consistently achieved profit growth every year from FY13 to FY24."
๐Ÿ‘4๐Ÿ‘2๐Ÿ”ฅ1๐Ÿ‘Œ1
Expansion plan

Lincoln Pharmaceuticals expansion strategy involves registering new products for export, increasing its market presence, and leveraging its state-of-the-art manufacturing facilities to meet international standards. In FY25, company will continue to expand its global and regional footprints while building a strong portfolio in lifestyle and chronic segment especially women healthcare, dermatology to complement its strong presence in the acute segment. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, no-term debt, and healthy return ratios. Committed to R&D and innovation, company has a strong lineup of over 1,700 registered products and 700 more in development
๐Ÿ”ฅ3โšก1๐Ÿ‘1๐Ÿ‘Œ1
Export

Lincoln Pharmaceuticals exports to 60+ countries spanning East & West Africa, Central & North America, Latin America, and Southeast Asia. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion, while also aggressively pursuing product registration for its Cephalosporin plant in Mehsana. These initiatives align with the company's revenue target of Rs. 750 crore for FY26.
๐Ÿ‘4๐Ÿ‘Œ3๐Ÿ”ฅ2
Company Outlook

Lincoln Pharmaceuticals is progressing well on its long-term growth roadmap. In FY24, the company will continue to build a strong portfolio in lifestyle and chronic segments especially women healthcare, dermatology to complement its strong presence in the acute segment. Company has set a target of achieving Rs. 750 crore revenue by FY26 while maintaining or improving its
๐Ÿ‘6โšก1๐Ÿ‘1๐Ÿ‘Œ1
Lincoln Pharmaceuticals Ltd 515-615
Expected level 800
Support 480
๐Ÿ”ฅ12๐Ÿ‘9โค3โšก1
Good morning
๐Ÿ‘12๐Ÿ†’3๐Ÿ‘2๐Ÿพ1
๐ŸชฆBest In METALS

a) Tata steel

b) Hindalco

c) SAIL

d) JSW steel
๐Ÿ‘28โšก5๐Ÿ”ฅ5โค1
๐ŸงชCHEMICALS SECTOR

Deepak Nitrite
โšก21๐Ÿ”ฅ10๐Ÿ‘7โค3
Affle (India) Ltd Company Details

Affle (India) Ltd is a global technology company with a proprietary consumer intelligence platform that delivers consumer engagement, acquisitions and transactions through relevant mobile advertising. The platform aims to enhance returns on marketing investment through contextual mobile ads and also by reducing digital ad fraud. Affle powers unique and integrated consumer journeys for marketers to drive high ROI, measurable outcome-led advertising across global connected devices.The company has been a long-trusted partner for many of the worldโ€™s biggest B2C brands across the industry verticals. Affle is enabling innovative, on-the-go and digitally empowered ways for the advertisers to deeply engage with consumers. The company primarily operates in emerging markets like India, South East Asia, Middle East & Africa and LATAM. The company has two business segments : โ€ข Consumer platform โ€“ The platform provides services such as new consumer conversions (acquisitions, engagements and transactions) through relevant mobile advertising, retargeting existing consumers to complete transactions for e-commerce companies through relevant mobile advertising and an online to offline (โ€œO2Oโ€) platform that converts online consumer engagement into in-store walk-ins. The consumer platform is used by business to consumer (โ€œB2Cโ€) companies across industries, including e-commerce, fin-tech, telecom, media, retail and FMCG companies, both directly and indirectly through their advertising agencies. Some of the customers includes Apollo 24|7, Motilal Oswal, Swiggy, Zepto, Angel One, etc. The company primarily earns revenues from its consumer platform on a Cost Per Converted User (CPCU) basis (contributes ~93% of consumer platform revenue), which comprises user conversions based on consumer acquisition and transaction models. It also earns revenue through awareness and engagement type advertising (Non-CPCU), which comprises cost per thousand impressions (CPM), cost per view (CPV) and cost per click (CPC) models.
Enterprise platform โ€“ This platform offers an integrated approach to building audience centric mobile assets and comprise app development for third parties, enabling offline to online commerce for offline businesses with e-commerce aspirations, enterprise grade data analytics for online & offline companies and cloud services . While most of the industry is largely dominated by companies operating on clicks, views and impressions, Affle, with its differentiated business model drives CPCU based conversions for advertisers primarily focused on emerging markets and across the industry verticals. Most of these conversions are deeply linked to the deep funnel matrix which are always post click and post app install CASE STUDY events done by the consumers on their smart devices.
๐Ÿ‘8๐Ÿ”ฅ5โšก2๐Ÿ˜1
#SALES #GROWTH 5 Year CAGR 49.2%

In FY24, the net sales witnessed a growth of 28.5% YoY and stood at โ‚น1,843 cr. This was on account of growth in India & Emerging Market and on account of acquisition of YouAppi. Excluding the impact of acquisition, the revenue grew by 15%. The CPCU business witnessed strong momentum resulting in a significant increase in converted users by 22% YoY to 31.3 cr with CPCU rate increased by 10% to โ‚น56.2. The growth in the CPCU rates was on account of companyโ€™s focus towards premium consumers. During Q1 FY25, the net sales witnessed a growth of 27.8% YoY and stood at โ‚น520 cr. This was on account of growth across all the geographies. Excluding the impact of acquisition, the revenue grew by 20%. The CPCU business witnessed strong momentum resulting in a significant increase in converted users by 32% YoY to 9.1 cr with CPCU rate increased by 4% to โ‚น57.
๐Ÿ‘6โšก3๐Ÿ‘1
#EBITDA #GROWTH 5 Year CAGR 38.6%

In FY24, the EBITDA stood at โ‚น360 cr, recording a growth of 24.7% YoY. The data & inventory cost (~61% of revenue) and employee costs (~13% of revenue) increased significantly on a YoY basis in line with the revenue growth. They continued to strategically invest in the inventory and data costs as they are calibrating their platform to premium inventory touchpoints. In H2 FY24, the management increased their spending on marketing cost and trade events in the international markets. They would continue to spend in FY25 as well. During Q1 FY25, the EBITDA stood at โ‚น104.5 cr, recording a growth of 33.8% YoY on account of improved operational efficiencies.
โšก4๐Ÿ‘4๐Ÿ”ฅ1
#PAT #GROWTH 5 Year CAGR 43.5%

In FY24, the PAT stood at โ‚น297 cr, recording a growth of 20.8% YoY. During Q1 FY25, the PAT stood at โ‚น86.6 cr, recording a growth of 30.9% YoY. Effective tax rate stood higher for the company at 18.7%, and this is going to be the new standard for them.
๐Ÿ”ฅ6๐Ÿ‘2
#EBITDA #MARGIN

in FY24, the EBITDA margin contracted by 61 bps YoY and stood at 19.5%. During Q1 FY25, the EBITDA margin stood at 20.1%. On a YoY basis, there has been a marginal expansion in the EBITDA margin by ~89 bps.
โšก2๐Ÿ‘2๐Ÿ‘1๐Ÿ‘Œ1
#Management #Comments

The management has a vision to develop the market share and build a robust portfolio of services that will help them to get long term sustainable growth. With the Affle 2.0 strategy, the management is focusing on being a leader in the Indian market, verticalization of AI innovations, penetrate vernacular section of India and create an omni-channel connected ecosystem. The recent fund-raising activity will help to build a robust business structure in the future either through organic or inorganic routes. During the quarter, the management appointed four new board of directors to provide accountability and enhance the depth of expertise.
๐Ÿ‘Œ3๐Ÿ‘2๐Ÿ”ฅ1
#Company #Potential

The total global digital ad spend is expected to increase at a CAGR of 16% from $381 bn in 2020 to $785 bn by 2025. โ€ข The global average digital ad spend as a percentage of total advertising market is ~63%. โ€ข The total advertisement industry in India is expected to grow at a CAGR of 15% from โ‚น85,769 cr in 2022 to โ‚น1,13,575 cr by 2025. โ€ข The digital ad spends in India as a percentage of total advertising market is ~35% in 2022 which is expected to increase to 42%45% by 2024. This growth is attributed to the consistent improvement in digital infrastructure, governmentโ€™s push to boost the digital economy, growing internet penetration, rise in smartphone adoption, innovation in mobile technologies and increased adoption of digital payments. โ€ข The total digital ad spend in India is expected to grow at a CAGR of 30% from โ‚น29,784 cr in 2022 to โ‚น51,110 cr by 2025. โ€ข E-Commerce & FMCG makes the biggest contribution to the digital media industry. โ€ข Among the digital media advertising format, social media & online video format has been the largest. Online video has seen a strong growth owing to the low-cost smartphones and a high-speed connectivity in India. โ€ข Connected TV (CTV) devices represent a growing advertising opportunity thanks to the expansion of free ad-supported streaming TV (FAST) services and the continued growth of premium online video. However, CTV ownership in India is far behind other markets with only 10% of homes owning a CTV set, due to the growth of adoption and usage of smartphones, which had a 60% penetration of population in 2022 that could increase up to 80% in 2026.
๐Ÿ‘8โšก2๐Ÿ”ฅ1๐Ÿ‘1